



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34076

Title: TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR IN CHRONIC HEPATITIS B: TENOSIMP-B STUDY

Reviewer’s code: 03210617

Reviewer’s country: China

Science editor: Yuan Qi

Date sent for review: 2017-03-29

Date reviewed: 2017-04-07

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This study focused on the efficacy and safety of Tenofovir disoproxil fumarate versus Lamivudine + adefovir in patients with chronic hepatitis B with prior failure with Lamivudine. Several points require further attention: 1. In clinical practice, obese people often accompanied with diabetes or hypertension which would lead to deterioration in renal function. Whether these patients included or not in the study population? 2. The patients with HBV-related cirrhosis or compensated fibrosis should be described in the study population, and the efficacy and safety of TDF and LAM+ADV should be analyzed among these patients.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34076

Title: TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR IN CHRONIC HEPATITIS B: TENOSIMP-B STUDY

Reviewer's code: 03664182

Reviewer's country: China

Science editor: Yuan Qi

Date sent for review: 2017-03-29

Date reviewed: 2017-04-11

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

According to recently research, TDF have been proved which can effectively rescue HBV drug resistance, and this research need to enroll more patients to demonstrate the difference between two groups. From economical point, given entecavir would be an option to save cost. List all patients' viral load at start of rescuing and monitor anti-virus responding.

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 34076

Title: TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR IN CHRONIC HEPATITIS B: TENOSIMP-B STUDY

Reviewer's code: 02942798

Reviewer's country: Slovakia

Science editor: Yuan Qi

Date sent for review: 2017-03-29

Date reviewed: 2017-04-14

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

Dear sir, thank you for opportunity to review paper: Rodríguez M et al. TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR IN CHRONIC HEPATITIS B: TENOSIMP-B STUDY. Authors compared the maintenance of virologic response in patients with chronic hepatitis B with prior failure with LAM in patients treated by tenofovir v.s. lamivudine + adefovir. Design of the study is excellent, and study was well made. Duration of the phase IV study was 48 weeks. Sustained virologic suppression was 100% in both treated groups. All patients in both groups maintained HBeAg negativity during study period. None of the patients lost HBs antigen. Not only virologic response, but also adverse effects were comparable between tenofovir vs. lamivudine + adefovir study group. Adherence was slightly lower in lamivudine + adefovir study group, but not significantly. The total average hospital expense per patient was significantly lower in tenofovir group. Paper needs only minimal changes. 1) Abstract should be given at the beginning of an article. 2) Please add viral load and HBe/antiHBe status in the



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

patient with prematurely stopped treatment (tenofovir) due to adverse reactions. I recommend to accept paper for publication in World journal of gastroenterology.